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a  b  s  t  r  a  c  t
Background:  In  recent  years,  some  studies  were  conducted  to evaluate  the  effects  of  stem  cells  from
different  sources  on patients  with  spinal  cord  injury  (SCI).  This  study  was  carried  out  to evaluate  the
feasibility  and therapeutic  potential  of  autologous  bone  marrow  cell (BMC)  transplantation  in 11  complete
spinal  cord  injured  patients  at thoracic  level.
Methods and  materials:  This  nonrandomized  clinical  trial  compared  the  results  of  autologous  BMC  trans-
plantation  into  cerebrospinal  ﬂuid  (CSF)  via  lumbar  puncture  (LP)  in  11  patients  having  complete  SCI,
with  20  patients  as  control  group  who  received  conventional  treatment  without  BMC transplantation.
The  patients  underwent  preoperative  and follow-up  neurological  assessments  using the  American  Spinal
Injury Association  (ASIA)  impairment  scale.  Then,  the  participants  were  followed  for  12–33  months.
Results:  Eleven  patients  with  the  mean  age  of 33.2  ± 8.9 years  and  20 patients  with  the  mean  age  of
33.5  ± 7.2  years  were  enrolled  in the  study  and  in the  control  group,  respectively.  None  of the patients  in
the study  and control  group  experienced  any  adverse  reaction  and  complications,  neither  after  routine
treatment  nor  after  cell  transplantation.  Five  patients  out  of 11  (45.5%)  in the  study  group  and  three
patients  in  the control  group  (15%)  showed  marked  recovery,  but  the  result  was  statistically  borderline
(P =  0.095).
Conclusion:  We  conclude  that  transplantation  of  autologous  BMC  via  LP  is  a feasible  and safe  technique,
but  at  the  moment,  no  clear  answer  can  be  given  regarding  the  clinical  potential,  despite  a  potential
ents,tendency  to treat  SCI pati
. Introduction
Traumatic injury to spinal cord often leads to severe disability
n patients and encompasses approximately 150,000–200,000 new
pinal cord injury (SCI) cases annually worldwide.
Because of the signiﬁcant loss of function and ﬁnancial costs and
he fact that previous trials have not demonstrated good results [1],
ransplantation of a variety of tissues and cells to treat SCI patients
as been suggested. Stem cells transplanted into spinal cord lesions
ay  help improve regeneration and spinal cord function. Various
ypes of embryonic stem cells and adult stem cells have been shown
o contribute to the axonal regeneration following SCI [2,3].
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It has also been suggested that bone marrow cells (BMC) can be
used in SCI patients effectively, and recently, it has been used in
some clinical studies [4–9].
Although the implantation of stem cells via lumbar puncture
(LP) appears to be safe [8–10], fever, headache, and tingling sen-
sation have been reported [8].  Moreover, autologous BMCs would
also obviate ethical problems associated with the use of embryonic
stem cells [6,7,9,11,12]. The major attraction of BMC  transplanta-
tion approach is the ease of obtaining patient’s autologous tissue
at the bedside for transplantation [6]. In addition, BMCs are har-
vested simply with considerable growth in the culture. These
properties make them ideal candidates for cell therapy procedures.
Therefore, some investigators suggest that autologous BMC  trans-
plantation could be a suitable technique to treat SCI patients. BMCs
can be administrated into the injury site [6,13,14] or remote from
the injury through either intravenous and intraarterial [15,16] or
intrathecal routes [5,8–10,17].  The use of LP for the delivery of stem
cells in SCI patients seems to be minimally invasive and allows safe
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pinal cord [9,10,18]. Only a few clinical trials of cell transplantation
n acute and subacute SCI patients have been reported [6,11,19,20].
e performed a clinical trial study for the clinical evaluation of
afety and efﬁcacy of the expanded autologous bone marrow trans-
lantation via LP in thoracic and upper lumbar SCI patients within
4–43 days following the onset of injury.
. Methods and materials
.1. Patient selection
A nonrandomized phase I/II evaluation of clinical safety and efﬁ-
acy of autologous BMC  in subacute spinal cord injured patients was
arried out. The patients in both groups were selected from com-
lete SCI patients (American Spinal Injury Association [ASIA] grade
) who were admitted to Bahonar University Hospital, Kerman,
ran, from December 2006 to August 2009. The stem cell laboratory
ould service the project only from January 2007 to June 2007 and
he patients in the study group were selected consequently in this
eriod of time. The patients in the control group were selected non-
onsecutively and randomly before and after this period of time and
articipants in both groups signed the informed consent form. All
he patients in the study and control group received conventional
urgery, medical treatment, and rehabilitation.
.2. Selection criteria
.2.1. Inclusion criteria
Acute (<2 weeks after SCI) and subacute (2–8 weeks after SCI)
atients with complete SCI at thoracic level, ASIA grade A and a
ontusion conﬁrmed by MR  images, age between 10 and 50 years,
nd injury level from T1–L1 vertebra were the inclusion criteria.
.2.2. Exclusion criteria
The exclusion criteria included any improvements in the neu-
ological functions before the cell therapy and during the cell
reparation period and serious preexisting medical diseases, such
s diabetes mellitus, autoimmune diseases, carcinoma, and hyper-
ension.
Standard neurological classiﬁcation of SCI was performed
ccording to the ASIA protocol [1] to evaluate the neurological
eﬁcit. Two neurosurgeons who were unconnected to the study
valuated any neurological improvement in the SCI patients fol-
owing the intervention. The evaluation was done in both study and
ontrol group, and each of the examiners examined the patients in
oth groups. The follow-up examinations were carried out every
hree months after the BMC  transplantation.
.3. Preparation of bone marrow stromal cells
All the chemicals were purchased from Sigma Company
Sigma–Aldrich, St Louis, Mo,  USA) unless stated otherwise.
e used the procedure for the culture of BMCs, which has
een described elsewhere, with minor modiﬁcation [21]. Twenty
illiliters of bone marrow were aspirated from the iliac crest and
ransferred to the cell culture laboratory within 1 h. In the labora-
ory, the bone marrow was carefully layered on the top of 3 ml  of
coll solution and centrifuged at 350 × g for 10 min. The buffy coat
ayer at the interface was carefully removed using a ﬁre-polished
asteur pipette and transferred into a 10-ml sterile tube. The buffy
oat was mixed with 5 ml  of PBS containing 5.5 mM glucose and
entrifuged at 250 × g for 7 min. The cell pellet was removed from
he bottom of the tube and transferred into a 75 cm2 culture ﬂask
Falcon). Subsequently, 15 ml  of complete culture medium were
dded to the ﬂask. The complete culture medium was DMEM–F12
upplemented with 15% FBS (Gibco, UK), 100 IU/ml of penicillin,d Neurosurgery 114 (2012) 935– 939
60 g/ml of streptomycin sulfate, and 50 g/ml of amphotricin B.
The culture ﬂasks were incubated at 37 ◦C humidiﬁed atmosphere
with 5% CO2. After 24 h, the ﬂoating cells were removed, and the
cultures were washed thrice with pre-warmed PBS. Subsequently,
15 ml  of DMEM–F12, supplemented with 10% FBS, 1/100 (v/v)
insulin–transferrin–selenium solution, and antibiotics, were added
to the ﬂask and incubated at the same conditions. The medium was
refreshed every four to six days according to the rate of cell propa-
gation. When the attached cells reached >90% conﬂuence, the cells
were detached from the substratum with 3 ml  of 0.5 g/l trypsin and
0.2 g/l of EDTA. Then, 6 ml  of patient’s cerebrospinal ﬂuid (CSF) were
collected in a sterile tube via LP and transferred to the cell culture
laboratory. The BMCs were suspended in 3 ml  of the patient’s CSF
thoroughly and centrifuged at 250 × g for 7 min. The cell pellet was
resuspended in 3 ml  of the patient’s CSF. Subsequently, 20 l of the
suspension were mixed with 20 l of 0.04% trypan blue, and the
number of viable cells was counted with an improved Neubauer
chamber. The remaining suspension containing 7 ×105 to 1.2 × 106
viable BMCs was transferred to the operation room for LP admin-
istration.
2.4. Adipogenic and osteogenic differentiation of human BMCs
Samples of mononuclear cells were cultured on clean sterile
glass slides for 1 week, after which osteogenic and adipogenic dif-
ferentiations were induced for 14 and 21 days, respectively. The
osteogenic medium was DMEM–F12, supplemented with 10 nM
dexamethasone, 10 mM -glycerophosphate, 50 g/ml of ascor-
bic acid, and 10% FBS. The adipogenic medium was DMEM–F12,
supplemented with 100 nM dexamethasone, 50 g/ml of ascorbic
acid, 50 g/ml of indomethacin, and 10% FBS. The cells cultivated
in DMEM–F12 with 10% FBS served as the control. The medium was
refreshed every three to four days. The cells were stained with Oil
red O and Von-kossa to determine the adipogenic and osteogenic
differentiations of the induced cells, respectively.
2.5. Treatment
All the patients were operated to get reduction and ﬁxation and
received high dose of methyl prednisolone when applicable. After
BMC preparation, 7 × 105 to 1.2 × 106 viable BMCs were injected
into CSF via lumbar region at L3–L4 level by LP needle (18G) slowly
during about 1 min. Lumbar puncture was performed in the oper-
ation room to be sure more about sterility. The BMC-receiving
patients and those in the control group underwent neurological
examinations every three months.
Both the groups were given supervised physiotherapy (includ-
ing physical exercise, functional electro-stimulation, ultrasonic
diathermy, and infrared) [22] – three hours per day, three days a
week – and it continued throughout the study period.
The local ethics committee at Kerman University of Medical Sci-
ences, Kerman, Iran, approved the study protocol (agreement No.
K/87/47). The patients were aware of the research project as well as
the probable risk factors associated with it. All the procedures were
performed after obtaining a written informed consent from the
patients. We  certify that all the applicable institutional and govern-
mental regulations concerning the ethical use of human volunteers
were followed during the course of this research.
Fisher’s exact test was  used to compare the treatment success
rate between the study and control groups.
3. Results3.1. Characterization and differentiation of BMCs
Most of the cells were attached to the substratum shortly after
the culture, and the non-adherent cells were discarded during the
S. Karamouzian et al. / Clinical Neurology and Neurosurgery 114 (2012) 935– 939 937











































Mean age 33.18 ± 8.9 33.5 ± 7.16 0.914
Range 23–48 22–48
Male gender 63.6% 85.0% 0.210
Fracture type
Fracture dislocation 54.5% 50% 0.571
Burst fracture 45.5% 35%
Other 0% 15%
Fracture level
T1–T11 54.5% 40% 0.477
T12–L1 45.5% 60%
Prednisolone therapy 72.7% 75% 1.0
Decompressive laminectomy 0% 10% 0.527
Pain 72.7% 65% 1.0ere induced to differentiate into adipocyte (B) and osteocyte (C) for 14 and 21 days,
espectively. Cells in the control group showed few adipocytic (D) and no osteocytic
ifferentiation (E). Original magniﬁcation: (A and D) 100× and (B, C and E) 200×.
ashing steps. Fibroblast-like cells were observed after 48 h in
ost of the samples. Other cell types, including fusiform cells –
ells with extensive cytoplasmic processes – and roughly round
ells were also present in the culture. Nine days after the ini-
iation of adipogenic induction, cells with small lipid vacuoles
ere detectable when viewed under a phase contrast inverted
icroscope (Olympus IX70, Japan). The number of adipocytes and
ipid vacuoles increased with time. In the control group, very
ew adipocytes were detected after 14 days. Van-kossa staining
evealed calcium phosphate deposits in the extracellular matrix.
n addition, osteocyte-like cells with extensive cytoplasmic pro-
esses were also observed (Fig. 1). In non-induced cells, no calcium
hosphate deposit was detected.
.2. Patients
Eleven patients, seven males and four females, with mean age
f 33.2 ± 8.9 years enrolled in this study. Two patients in the con-
rol group refused to participate in the study due to their problem
n transportation, therefore, a total of 20 patients, 17 males and
hree females with mean age of 33.5 ± 7.2 years, were included in
he control group. Five cases in the study group and 12 cases in the
ontrol group suffered from spinal fracture at T12 and L1 levels,
nd the others had fracture at other thoracic levels. Both groups
ere comparable with respect to age (P = 0.91), gender (P = 0.21)
nd level (P = 0.48). According to the time window between the
nset of injury and transplantation (more than two  weeks), the
atients were considered to be in subacute phase [6].  The majority
f the patients in the study and control groups received methyl-
rednisolone, but three cases in the study group and ﬁve cases
n the control group did not receive methylprednisolone due to a
elay in admission to the hospital. Only two cases in the control
roup underwent decompressive surgery in addition to ﬁxation
nd fusion. The patients in the study group received autologous
MCs within 27.3 ± 8.4 (range: 14–43) days after SCI. The meanFollow up period 20.3 23.4 0.227
Marked recovery 45.5% 15.0% 0.095
follow-up period in the study and control groups was 20.3 ± 7.2
(range: 12–33) and 23.4 ± 5.6 (range: 12–32) months, respectively.
The patients were examined every three months. The major recov-
ery was obtained up to the sixth months, and after that, no major
recovery was  detected in the patients.
In the cell transplanted group, marked recovery (a two-grade
improvement from baseline, i.e. from ASIA A to ASIA C) was
reported in ﬁve patients (45.5%), when compared with 15%
improvement in the control group, reﬂecting a clinically meaning-
ful improvement, but there was  no statistical difference (P = 0.095).
In these cases, ASIA motor score in lower limb increased from 0
to 19.3 ± 1.5, and the sensory scores increased by 11.5 points, and
the patients were able to walk by brace. However, in the control
group, three patients improved from grades A to C (15%). None of
the patients experienced any detected complications after the rou-
tine treatment, such as CSF leakage, infection, or screw malposition.
Because of the lack of enough information about the complications
of stem cell therapy, we  evaluated the reported complication and
routine complications of LP after stem cell therapy, so we did not
evaluate some unknown complications of stem cell therapy such
as urinary tract infection. However, we did not observe any com-
plication in the study and control groups at the operation site. In
addition, no detectable complications that could be related to stem
cell therapy were found after cell transplantation in two  days of
hospitalization or long-term follow-up period. Eight patients in the
study group and 13 patients in the control group complained of
neuropathic pain, yet this difference was not statistically signif-
icant. The data from the study and control groups are shown in
Table 1.
4. Discussion
The present study demonstrated that 45.5% of the patients at
subacute stage showed improved neurological function after autol-
ogous BMCs transplantation, which is obviously higher than the
rate of improvement in the historical review [23] and our con-
trol group. However, despite the differences in the recovery levels
between the groups, the small number and heterogeneity of the
patients do not allow reliable analysis of the efﬁcacy. We  did not
ﬁnd any clinically adverse reaction of cell therapy, such as fever and
headache. Pain was  seen more frequently in the study group (73%),
but it was  not signiﬁcant (Table 1).
Cell transplantation for SCI treatment is a promising therapeutic
strategy, and its clinical application would be facilitated by non-
invasive delivery procedures. Bakshi reported that BMC  delivered
by LP reached the contused spinal cord tissues and exerted a signiﬁ-
cant beneﬁcial effect by reducing cyst and injury size [18]. However,
938 S. Karamouzian et al. / Clinical Neurology and Neurosurgery 114 (2012) 935– 939
Table  2
A review of the characteristics and outcome of patients with acute and subacute SCI after autologous BMC  transplantation.
Our study Park et al. [11] Yoon et al. [6] Sykova et al. [16,19]
Mean age 33.18 ± 8.9 36 29.4 ± 13.5 37.5
Range 23–48 17–51 NA 21–41
Injury stage Sub-acute Acute Acute and sub-acute Acute and sub-acute
Injury  level
Thoracic 11 1 10 1
Cervical 0 5 13 3
Total  11 6 23 4
Time  of stem cell therapy after SCI 14–43 days 7 days 2–8 weeks 10–33 days
Cell  type Autologous BMC Autologous BMC Autologous BMC Mononuclear BMC
Cell  propagation Yes No No No
Route  of treatment LP Injury site Injury site IA
Combined therapy None G-CSF (subcutaneous) CM-CSR G-CSF
Follow  up period 12–33 months 6–18 months 10.1–11.3 months 12 months
Improvement
A  to B 0 4 (66%) NA
A  to C 5 (45.5%) 1 (16.6) NA 1 (25%)
A  to B and C 5 (45.5%) 5 (83.3%) 30.4% 1 (25%)a









































ia Data are obtained from Table 1 (Sykova et al. [16,19]).
e could not ﬁnd any evidence that shows that LP itself has an effect
n the neurological outcome after SCI.
The clinical application of stem cells to treat SCI patients has
een reported in the past few years [6,7,9–11,16,24,25].  BMCs have
een used in the treatment of hematopoietic diseases for a long
ime without any immunological problem [26]. Therefore, the use
f BMCs would obviate ethical problems concerning the use of
mbryonic stem cells.
In the present study, the suggestions to conduct clinical trials for
CI patients [1] were fulﬁlled in a subacute group of thoracic and
pper lumbar SCI patients after cell propagation and transplanta-
ion via LP. Park et al., in a study group of six SCI patients with lesions
t cervical and thoracic levels, reported an improvement from A to
 and/or C in ﬁve patients after direct BMC  transplantation at the
njury site combined with subcutaneous injection of G-CSF [11].
lso, in a controlled clinical trial, transplantation of BMCs into the
njury site of SCI patients in acute phase resulted in 29.5% neuro-
ogical improvement from AISA A to B or C, while in the subacute
reatment group, 33.3% of the patients improved to AISA B or C [6].
lthough we did not administer G-CSF or GM-CSF, the improve-
ent rate in our patients was comparable with that observed by
oon et al. [6].  However, in the report of Park et al., the improve-
ent rate was much higher (ﬁve of six cases) than that of our study
s well as the study by Yoon et al. Park et al. limited their study
o patients having cervical cord injury in acute phase, which can
xplain the higher rate of improvement [27]. The results of a mul-
icenter phase 2 study of cell therapy in acute SCI patients have not
et been reported for comparison. In that study, the researchers
sed invasive method of direct injection of autologous cells. How-
ver, they emphasized on less invasive method of intrathechal cell
nfusion [20]. Data from some reported clinical studies in acute and
ubacute phases are shown in Table 2 [16].
Due to astrocytic scarring at the injury site, cell transplantation
nto a chronic SCI is not able to remyelinate the axons [28]. This may
tand for the poor results of stem cell transplantation in chronic
CI patients. However, some improvements in chronic SCI patients
ave been reported after scar removal and transplantation of fetal
pinal cord fragment together with olfactory ensheathing cells [12]
s well as after transplantation of BMCs, both intravenously and
ocally into the cyst cavity [14]. Good results have been reported
n some studies [4,8,14,15],  and the higher rate of improvement in
ome of these reports [15,24] may  be due to the high number of
mplanted stem cells.Demyelination of spared axons is a prominent feature of SCI.
High number of demyelinating axons has been observed on the
ﬁrst day at the injury epicenter. This demyelination decreases sub-
stantially by the seventh day of the injury [28]. In addition to
demyelination, SCI also results in a period of secondary degener-
ation characterized by substantial cellular loss, inﬂammation, and
axonal degeneration. The number of demeylinating axon markedly
increases in 120 and 450 days post-injury [28].
Bone marrow stem cells can differentiate into mature neuron
or glial cells in vitro as well as in vivo [29,30],  may  improve the
neurological deﬁcits by generating either neural cells or myelin
producing cells [31], and can promote axonal regeneration by guid-
ing nerve ﬁbers [32].
The precise mechanism by which transplantation of BMCs pro-
motes functional recovery after SCI is still unclear. One  explanation
is that factors secreted from the BMCs ameliorate functional deﬁcits
[2].  Among these factors are the cytokines that may  be neuropro-
tective and enhance regeneration. Some cytokines, such as Colony
Stimulating Factor (CSF), Nerve Growth Factor (NGF), Brain Derived
Neurotrophic Factor (BDNF), and Vascular Endothelial Growth Fac-
tor (VEGF), have been shown to assist nervous tissue regeneration
[33]. Remyelination is another possible explanation that has been
addressed in some other studies [34].
Sykova et al. recommended “the therapeutic window of 3 to 4
weeks following injury for stem cell treatment [16]. Many other
researchers consider 10 to 14 days after SCI as an optimal time
period for cell transplantation, but neurologic improvement of a
few patients in whom cell transplantation was performed between
two and eight weeks after injury has been reported by Yoon et al.
[6]. Our results are in agreement with their statement that “the
optimal time period of BMC  transplantation in SCI patients should
not be restricted to patients less than two weeks post-injury.”
By the exclusion/inclusion criteria, we tried to decrease the
impact of confounding variables, such as age, level of injury, and
severity of injury. There was no signiﬁcant difference between the
two groups according to some other confounding factors, such
as type of fracture, prednisolone therapy, gender, level, and age
(Table 1). The present study was performed on a limited number of
SCI patients, which may  inﬂuence the interpretation of the result,
which was  statistically borderline. In addition, the strategy requires
some time for cell preparation and expansion, which may  affect the
therapeutic window of the cell transplantation as well as the num-
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uch as patients with complete ASIA A at the thoracic level who are
requently suggested as being the preferred group of SCI patients for
he early phase of SCI clinical trials [35]. Our LP route of cell delivery
as not time-consuming and invasive, and we  did not observe any
omplications, such as fever and other risks of open surgery.
. Conclusion
We  conclude that BMC  grafting via LP is safe; however, at the
oment, no clear answer can be given regarding the motor and
ensory function of thoracic SCI patients, despite a potential ten-
ency observed through transplantation of BMC. We  recommend
hat the therapeutic value of such treatments should be evaluated
n a more comprehensive multicenter study.
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